The metabolic effects of insulin and rosiglitazone combination therapy in Chinese Type 2 diabetic patients with nephropathy

Medical Science Monitor

Volumn 10, Issue 3, 2004, Pages

  Chan, Norman N ^a   Tong, Peter C Y ^a   So, Wing Yee ^a   Leung, Wilson Y S ^a   Chiu, Cherry K P ^a   Chan, Juliana C N ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Diabetes; Diabetic nephropathy; Insulin; Rosiglitazone

Indexed keywords

GLUCOSE; INSULIN; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; INSULIN TREATMENT; KIDNEY FAILURE; LIPID BLOOD LEVEL; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; SIDE EFFECT; WEIGHT GAIN;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 1542615719     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Lippert J, Ritz E, Schwarzbeck A, Schneider P: The rising tide of endstage renal failure from diabetic nephropathy type II - an epidemiological analysis. Nephrol Dial Transplant, 1995; 10: 462-67
2. US Renal Data System: USRDS, 1999 annual data report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1999; 25-38
3. Ritz E: Nephropathy in type II diabetes. Exp Clin Endocrinol Diabetes, 1997; 105(Suppl 2): 80-82
4. UKPDS: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998; 352: 837-53
5. Chan NN, Brain HP, Feher MD: Metformin-associated lactic acidosis: a rare or very rare clinical entity? Diab Med, 1999; 16: 273-81
6. DeWitt DE, Hirsch IB: Outpatient insulin therapy in type I and type 2 diabetes mellitus: scientific review. JAMA, 2003; 289: 224-64
7. Schwartz S, Raskin P, Fonseca V, Graveline JF: Effect of troglitazone in insulin treated patients with type 2 diabetes. N Engl J Med, 1998; 338: 861-66
8. Raskin P, Rendell M, Riddle MC et al, for the Rosiglitazone Clinical Trials Study Group: A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diab Care, 2001; 24: 1226-32
9. Buch HN, Baskar V, Barton DM et al: Combination of insulin and thiazolidinedione therapy in massively obese patients with type 2 diabetes. Diab Med, 2002; 19: 572-74
10. Castelli WP: The new pathophysiology of coronary heart disease. Am J Cardiol, 1998; 82: 60T-65T
11. Freed MI, Ratner R, Marcovina SM et al: Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes. Am J Cardiol, 2002; 90: 947-52
12. Asano T, Wakisaka M, Yoshinari M et al: Peroxisome proliferator-activated receptor gamma 1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation. Biochim Biophys Acta, 2000; 1497: 148-54
13. Haffner SM, Greenberg AS, Weston WM et al: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation, 2002; 106: 679-84
14. Nicholas SB, Kawano Y, Wakino S et al: Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension, 2001; 37: 722-27
15. Faich GA, Moseley RH: Troglitazone (Rezulin) and hepatic injury. Drug Saf, 2001; 10: 537-47
16. Isshiki K, Haneda M, Koya D et al: Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes, 2000; 49: 1022-32
17. Nakamura T, Ushiyama C, Suzuki S et al: Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diab Med, 2001; 18: 308-13
18. Yamashita H, Nagai Y, Takamura T et al: Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metabolism, 2002; 51: 403-8
19. Scheen AJ: Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf, 2001; 24: 873-88
20. Lebovitz HE, Kreider M, Freed MI: Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diab Care, 2002; 25: 815-21
21. Haban P, Simoncic R, Zidekova E, Ozdin L: Role of fasting serum C-peptide as a predictor of cardiovascular risk associated with the metabolic X-syndrome. Med Sci Monit, 2002; 8: CR175-79